858668-07-2

Basic information

• Product Name: EMD 534085
• Synonyms: EMD 534085;N-[2-(Dimethylamino)ethyl]-N'-[[(2R,4aS,5R,10bS)-3,4,4a,5,6,10b-hexahydro-5-phenyl-9-(trifluoromethyl)-2H-pyrano[3,2-c]quinolin-2-yl]methyl]urea
• CAS NO: 858668-07-2
• Molecular Formula: C25H31F3N4O2
• Molecular Weight: 476.5344496
• Mol File: 858668-07-2.mol

Chemical Properties

• Boiling Point: 609.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.195
• PKA: 13.78±0.46(Predicted)
• CAS DataBase Reference: EMD 534085(CAS DataBase Reference)
• NIST Chemistry Reference: EMD 534085(858668-07-2)
• EPA Substance Registry System: EMD 534085(858668-07-2)

Safety Data

• Hazardous Substances Data: 858668-07-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
EMD 534085 is used as a research tool for studying the role of γ-secretase in various biological processes and its potential therapeutic applications in Alzheimer's disease and other neurodegenerative disorders.
Used in Alzheimer's Disease Research:
EMD 534085 is used as a selective inhibitor of γ-secretase to investigate its role in the processing of amyloid precursor protein and the generation of amyloid beta peptides, which are implicated in the pathogenesis of Alzheimer's disease.
Used in Neurodegenerative Disorder Research:
EMD 534085 is used as a valuable tool for understanding the molecular mechanisms underlying neurodegenerative disorders and for the development of potential treatments.
Used in Drug Development:
EMD 534085 is used as a starting point for the development of potential treatments for Alzheimer's disease and other neurodegenerative disorders by modulating the activity of γ-secretase.

Upstream product

• 108-00-9 N,N-dimethylethylenediamine 
• 1161831-78-2 exo-(2R,4aS,5R,10bS)-5-phenyl-9-trifluoromethyl-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-ylmethylamine (2R,3R)-(-)-di-O-benzoyl tartaric acid salt 
• 1161831-73-7 1-[(R)-1-(3,4-dihydro-2H-pyran-2-yl)methyl]-3-(2-dimethylamino-ethyl)-urea 
• 1161831-76-0 1-(2-dimethylamino-ethyl)-3-((2R,4aS,5R,10bS)-5-phenyl-9-trifluoromethyl-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-ylmethyl)-urea 
• 455-14-1 4-trifluoromethylphenylamine 
• 100-52-7 benzaldehyde 
• 3749-36-8 2-hydroxymethyl-3,4-dihydro-2H-pyran 
• 530-62-1 1,1'-carbonyldiimidazole 

Relevant articles and documents

Optical Control of Mitosis with a Photoswitchable Eg5 Inhibitor

Eg5 is a kinesin motor protein that is responsible for bipolar spindle formation and plays a crucial role during mitosis. Loss of Eg5 function leads to the formation of monopolar spindles, followed by mitotic arrest, and subsequent cell death. Several cell-permeable small molecules have been reported to inhibit Eg5 and some have been evaluated as anticancer agents. We now describe the design, synthesis, and biological evaluation of photoswitchable variants with five different pharmacophores. Our lead compound Azo-EMD is a cell permeable azobenzene that inhibits Eg5 more potently in its light-induced cis form. This activity decreased the velocity of Eg5 in single-molecule assays, promoted formation of monopolar spindles, and led to mitotic arrest in a light dependent way.

PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES

The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presen

POLYMORPHIC FORMS AND PROCESS

The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula (I) wherein R1, R2, R3, R6, R7 and Q are defined as in claim 1 as well as their crystal